Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells

Abstract

Malignant cells drive the generation of a desmoplastic and immunosuppressive tumor microenvironment. Cancer-associated stromal cells (CASC) are a heterogeneous population that provides both negative and positive signals for tumor cell growth and metastasis. Fibroblast activation protein (FAP) is a marker of a major subset of CASCs in virtually all carcinomas. Clinically, FAP expression serves as an independent negative prognostic factor for multiple types of human malignancies. Prior studies established that depletion of FAP(+) cells inhibits tumor growth by augmenting antitumor immunity. However, the potential for immune-independent effects on tumor growth have not been defined. Herein, we demonstrate that FAP(+) CASCs are required for maintenance of the provisional tumor stroma because depletion of these cells, by adoptive transfer of FAP-targeted chimeric antigen receptor (CAR) T cells, reduced extracellular matrix proteins and glycosaminoglycans. Adoptive transfer of FAP-CAR T cells also decreased tumor vascular density and restrained growth of desmoplastic human lung cancer xenografts and syngeneic murine pancreatic cancers in an immune-independent fashion. Adoptive transfer of FAP-CAR T cells also restrained autochthonous pancreatic cancer growth. These data distinguish the function of FAP(+) CASCs from other CASC subsets and provide support for further development of FAP(+) stromal cell-targeted therapies for the treatment of solid tumors.

©2015 American Association for Cancer Research.

Figures

Figure 1. Extent of the desmoplastic stromal response in mouse and human tumors correlates with the prevalence of intra-tumoral FAP+ stromal cells

(A) The extent of desmoplasia was evaluated in established tumors by H&E staining, Masson's trichrome staining to reveal collagen deposition (blue), Alcian blue staining for glycosaminoglycans (aqua blue), and reactivity for hyaluronan-binding protein (HABP) or anti-versican antibody. Scale: 100 μm. (B) Flow cytometry was performed to identify CD90+ stromal cells and CD45+ hematopoietic cells that express FAP. Data shown are normalized to total live tumor population and expressed as the mean ± SEM (n>5). * Denotes significant difference between each group, p value < 0.01.

Figure 2. FAP-CAR T cells confer anti-tumor activity in desmoplastic human lung cancer in immunodeficient hosts

(A) NSG mice bearing established A549 tumors received FAP-CAR human T cells i.v. (B) To test target-specificity of FAP-CAR T cells, NSG FAP-null tumor-bearing mice were injected i.v. with FAP-CAR human T cells. (C) NSG mice bearing I45 tumors were injected i.v. with FAP-CAR human T cells. The black arrow indicates the time of T cell transfer (n=5 per group). A549 tumors were harvested 8 days post-adoptive T cell transfer. Tumor sections were stained with antibodies against human-specific ki-67 (D) and cleaved caspase-3 (E) (n=3 per group). * Denotes statistical significance between untreated and FAP-CAR T cell-treated samples, p value

Figure 3. FAP-CAR T cells restrict tumor growth through decreasing stromagenesis and tumor angiogenesis in desmoplastic human lung cancer xenografts

Established A549 tumor-bearing mice were either injected i.v with FAP-CAR human T cells or left untreated. Tumors were harvested 8 days post-adoptive T cell transfer. Tumor sections were stained with antibodies against FAP (A) and α-SMA (B) to examine the degree of stromagenesis. Tumor tissues were stained with antibodies against CD31 (C) and NG2 (D) to reveal endothelium and pericytes, respectively. * Denotes statistical significance between untreated and FAP-CAR T cell-treated samples (n=3), p value

Figure 4. Depletion of tumor stroma by FAP-CAR T cells in desmoplastic human lung cancer xenografts

Established A549 tumor-bearing mice were treated with FAP-CAR human T cells. Tumors were harvested 8 days post-adoptive T cell transfer to evaluate the extent of desmoplasia. (A) Masson's trichrome staining was performed to determine collagen accumulation. (B) IHC was performed to reveal fibronectin content. (C) Alcian blue staining was performed to show total GAGs. Tumor tissues were stained with HABP (D) or anti-versican antibody (E). * and # denote statistical significance between untreated and FAP-CAR T cell-treated samples (n=3), p value

Figure 5. Immune-independent anti-tumor mechanisms play a key role in FAP-CAR T cell-induced growth inhibition in murine PDA

(A) Established 4662 tumor-bearing C57BL/6 and NSG mice were treated with FAP-CAR or MigR1 mouse T cells (n=5 per group). A second dose was given 6 days later. * and # denote statistical significance between MigR1 and FAP-CAR-treated samples in B6 and NSG mice, respectively (p value

Figure 6. FAP-CAR T cells impact stromagenesis and angiogenesis in murine PDA

Established 4662 tumor-bearing mice (n=6 per group) and autochthonous PDA-bearing KPC mice (n=3 per group) were treated with 2 doses of FAP-CAR mouse T cells. IHC was performed using tumor tissues harvested from mice 3 days after the second dose of T cell transfer. Tumor sections were stained with antibody against (A) FAP, (B) SMA, (C) CD31, and (D) NG2. * and # denote statistical significance between MigR1 and FAP-CAR T cell-treated samples, p value

Figure 7. FAP-CAR T cells resolve desmoplasia in murine PDA

Established 4662 tumor-bearing mice (n=6 per group) and autochthonous PDA-bearing KPC mice (n=3 per group) were treated with 2 doses of FAP-CAR or MigR1 mouse T cells. Tumor tissues were harvested 3 days after the second dose of T cell transfer to evaluate the extent of desmoplasia. (A) Collagen was evaluated by Masson's trichrome staining. (B) HA was evaluated by HABP and (C) versican determined by immunohistochemistry staining. * and # denote statistical significance between MigR1 and FAP-CAR T cell-treated samples, p value